SU2C Catalyst®

​SU2C Catalyst® is a new collaborative initiative intended to leverage all stages of the pharmaceutical, biotechnology, diagnostic, and devices industries (collectively referred to herein as "industry") to bring new treatments to patients as rapidly as possible. SU2C is at the intersection between a large and highly skilled scientific community consisting of its Scientific Advisory Committee, Dream Teams, Translational Research Teams, and Innovative Research Grant recipients, academic institutions, and industry. SU2C Catalyst establishes a mechanism through which industry and academic scientists in the cancer community will conduct SU2C collaborative research projects that will deliver significant benefits for patients and society, accelerating the development of new treatments and, where appropriate, combination therapies. 

In October 2017, the AACR and SU2C announced that 10 clinical trials would be launched under SU2C Catalyst®​. Read the news release for details. As the Scientific Partner in SU2C Catalyst®​, the American Association for Cancer Research (AACR) provides scientific oversight and conducts expert peer review and grants administration for SU2C. 

The principles guiding SU2C collaborations with industry are designed to accelerate the pace of groundbreaking translational research that provides new therapies to patients rapidly:

  • Integrity: Industry, academia, and SU2C will act with integrity at all times, putting patients at the center of everything we do.

  • Independence: SU2C and affiliated researchers will maintain independent strategies, activities or information with unbiased scientific overview by its Executive Committee and associated Industry Steering Subcommittees.

  • Transparency: SU2C will be transparent, consistent, and fair when collaborating with industry.

  • Accountability: SU2C is accountable to many stakeholders and thus will not promote, endorse, or favor any particular product.


Updated: October 2017